Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
M Swamydas, EV Murphy, JJ Ignatz-Hoover… - Journal of Hematology & …, 2022 - Springer
Multiple myeloma is an incurable cancer characterized by the uncontrolled growth of
malignant plasma cells nurtured within a permissive bone marrow microenvironment. While …
malignant plasma cells nurtured within a permissive bone marrow microenvironment. While …
[HTML][HTML] The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy
Natural killer (NK) cells are innate lymphocytes that recognize and clear infected and
transformed cells. The importance of NK cells in tumor surveillance underlies the …
transformed cells. The importance of NK cells in tumor surveillance underlies the …
CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+ CS1 expressing CAR-T cells
J O'Neal, JK Ritchey, ML Cooper, J Niswonger… - Leukemia, 2022 - nature.com
Despite improvement in treatment options for myeloma patients, including targeted
immunotherapies, multiple myeloma remains a mostly incurable malignancy. High CS1 …
immunotherapies, multiple myeloma remains a mostly incurable malignancy. High CS1 …
Different evasion strategies in multiple myeloma
C Wang, W Wang, M Wang, J Deng, C Sun… - Frontiers in …, 2024 - frontiersin.org
Multiple myeloma is the second most common malignant hematologic malignancy which
evolved different strategies for immune escape from the host immune surveillance and drug …
evolved different strategies for immune escape from the host immune surveillance and drug …
Role of Immune Cells and Immunotherapy in Multiple Myeloma
The clinical signs of multiple myeloma, a plasma cell (PC) dyscrasia, include bone loss,
renal damage, and paraproteinemia. It can be defined as the uncontrolled growth of …
renal damage, and paraproteinemia. It can be defined as the uncontrolled growth of …
The safety and efficacy of radiation therapy with concurrent dexamethasone, cyclophosphamide, etoposide, and cisplatin-based systemic therapy for multiple …
Introduction The concurrent delivery of radiation therapy (RT) with salvage chemotherapies
in the management of relapsed and refractory multiple myeloma (MM) is an area of ongoing …
in the management of relapsed and refractory multiple myeloma (MM) is an area of ongoing …
Genetic predisposition for Multiple Myeloma. Identification and functional characterization of risk variants
LD Lozano - 2022 - portal.research.lu.se
Multiple myeloma (MM) is a blood malignancy originating from plasma cells. First-degree
relatives of patients with MM have two-to four-fold higher risk of MM. However, the molecular …
relatives of patients with MM have two-to four-fold higher risk of MM. However, the molecular …
[PDF][PDF] Genetic predisposition for Multiple Myeloma. Identification and functional characterization of risk variants
L Duran Lozano - 2022 - lucris.lub.lu.se
Multiple myeloma (MM) is a blood malignancy originating from plasma cells. First-degree
relatives of patients with MM have two-to four-fold higher risk of MM. However, the molecular …
relatives of patients with MM have two-to four-fold higher risk of MM. However, the molecular …